Last reviewed · How we verify
Tislelizumab，atezolizumab or Trastuzumab
Tislelizumab，atezolizumab or Trastuzumab is a Small molecule drug developed by Base Therapeutics (Shanghai) Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | Tislelizumab，atezolizumab or Trastuzumab |
|---|---|
| Sponsor | Base Therapeutics (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of NK510 to Treat Gastric Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tislelizumab，atezolizumab or Trastuzumab CI brief — competitive landscape report
- Tislelizumab，atezolizumab or Trastuzumab updates RSS · CI watch RSS
- Base Therapeutics (Shanghai) Co., Ltd. portfolio CI
Frequently asked questions about Tislelizumab，atezolizumab or Trastuzumab
What is Tislelizumab，atezolizumab or Trastuzumab?
Tislelizumab，atezolizumab or Trastuzumab is a Small molecule drug developed by Base Therapeutics (Shanghai) Co., Ltd..
Who makes Tislelizumab，atezolizumab or Trastuzumab?
Tislelizumab，atezolizumab or Trastuzumab is developed by Base Therapeutics (Shanghai) Co., Ltd. (see full Base Therapeutics (Shanghai) Co., Ltd. pipeline at /company/base-therapeutics-shanghai-co-ltd).
What development phase is Tislelizumab，atezolizumab or Trastuzumab in?
Tislelizumab，atezolizumab or Trastuzumab is in Phase 1.